Skip over global navigation links
U.S. Department of Health and Human Services

HHS aids development of next generation broad spectrum antibiotic

Date:  January 20, 2012

Company: CUBRC, Inc., of Buffalo, N.Y., and Tetraphase Pharmaceuticals of Watertown, Mass.

Contract amount: $11.4 million in the first year and can be extended an additional four years, for a total of five years and up to a total value of $67.2 million.

About the contract: This contract supports advanced development of a drug called TP-434, a novel antibiotic that potentially could treat illnesses caused by biological threats, such as anthrax and plague, as well as treat bacterial pneumonia and certain life-threatening bacterial infections associated with prolonged hospitalization. Tetraphase Pharmaceuticals currently is developing TP-434, a member of the tetracycline class of antibiotics, to treat complicated intra-abdominal infections. Early research and development indicates that TP-434 also could be effective against bacteria known to be resistant to many other antibiotics, including other tetracyclines. Today’s contract supports testing of TP-434 in clinical and animal studies as well as fine-tuning of drug manufacturing. The contract also supports development of both oral and intravenous formulations of TP-434.

Additional information: BARDA is seeking additional proposals for broad-spectrum antimicrobials that could potentially treat or prevent illness due to biological threat agents. Proposals are accepted through the Broad Agency Announcement BARDA-CBRN-BAA-11-100-SOL-00009 at www.fbo.gov.

PHE Newsroom

Submit an Inquiry

 

Watch, Listen, Subscribe

 
Facebook Exit Icon Twitter Exit Icon YouTube Exit Icon
Email via GovDelivery Exit Icon LinkedIn Exit Icon

  • This page last reviewed: April 28, 2017